Eli Lilly and Co Q3 2023 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Laura Hindley - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : So I think it's clear from your results that the mix system for Mounjaro is rapidly in progress. But how should we think about the ex-U.S. Trulicity contribution going forward, which did look weak this quarter? But at the moment, you're still supply restricted. Can we expect a return to growth into next year as constraints ease? Or should we now assume Trulicity is ex-growth as you put the shift into Mounjaro?

Question: Trung Huynh - UBS Investment Bank, Research Division - Analyst : Just one on Mounjaro U.S. pricing. So by our calculations, we think at 3Q '23, the net price is around $440 per [TRx]. For the rest of the year, do you think that net price can continue to go up and above the saving card price of $450? Are there payers willing to pay for this? Or is this broadly capped now until that saving card ends? And for next year, can you just give us your thoughts on if net price can meaningfully keep increasing?

Question: Nicole Germino - Truist Securities - Analyst : This is Nicole on for Robyn. Just going back to obesity. How are you thinking through the impact on Mounjaro if IRA stays and Wegovy and Ozempic prices decline in the 2026, 2027 time frame?